2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B1124A
    Fipexide hydrochloride 34161-23-4 99.88%
    Fipexide hydrochloride, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide hydrochloride reduces striatal adenylate cyclase activity. Fipexide hydrochloride has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide hydrochloride is used for senile dementia research. Fipexide hydrochloride acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection.
    Fipexide hydrochloride
  • HY-N0304R
    L-DOPA (Standard) 59-92-7
    L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease.
    L-DOPA (Standard)
  • HY-N10546
    Ganglioside GM1 37758-47-7 ≥99.0%
    Ganglioside GM1 is a member of the ganglioside family that can be used for neurological disease research. Ganglioside GM1 is a functional tissue receptor for the Cholera Toxin1.
    Ganglioside GM1
  • HY-P1298A
    Sauvagine TFA 98.76%
    Sauvagine TFA, a 40-amino-acid neuropeptide from the skin of the frog, is a mammalian CRF agonist. Sauvagine TFA is effective at releasing ACTH from rat pituitary cells. Sauvagine TFA possesses a number of pharmacological actions on diuresis, the cardiovascular system and endocrine glands.
    Sauvagine TFA
  • HY-P2242A
    RO27-3225 TFA 1373926-49-8 98%
    RO27-3225 TFA is potent and selective melanocortin 4 receptor (MC4R) agonist with an EC50 of 1 nM and 8 nM for MC4R and MC1R, respectively. RO27-3225 TFA shows ~30-fold selectivity for MC4R over MC3R. RO27-3225 TFA has neuroprotective and anti-inflammatory effects.
    RO27-3225 TFA
  • HY-P3561A
    Agouti-related Protein (AGRP) (83-132) Amide (human) (TFA)
    Agouti-related Protein (AGRP) (83-132) Amide (human) TFA is a fragment of agouti-related protein (AGRP) which is a protein found in abundance in the arcuate nucleus of the hypothalamus. AgRP primarily acts as an inverse agonist for the melanocortin-4 receptor (MC4R) to increase food intake.
    Agouti-related Protein (AGRP) (83-132) Amide (human) (TFA)
  • HY-U00431
    CCG 203769 410074-60-1 99.76%
    CCG 203769 is a selective G protein signaling (RGS4) inhibitor, which blocks the RGS4-Gαo protein-protein interaction in vitro with an IC50 of 17 nM.
    CCG 203769
  • HY-101884A
    Biotinylated-D-lysine TFA 99.32%
    Biotinylated-D-lysine TFA is a conjugate of L-biotin and D-lysine, where the carboxylate of L-biotin is coupled with the ϵ-amine of D-lysine via a secondary amide bond. Biotinylated-D-lysine TFA is an isomer of the neuroanatomical tracer Biocyte.
    Biotinylated-D-lysine TFA
  • HY-106441A
    Rislenemdaz 808732-98-1 99.86%
    Rislenemdaz (CERC-301) is an orally bioavailable and selective N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM, respectively.
    Rislenemdaz
  • HY-108235B
    (Rac)-Lanicemine 61890-25-3 ≥98.0%
    (Rac)-Lanicemine ((Rac)-AZD6765) is the racemate of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects.
    (Rac)-Lanicemine
  • HY-113316B
    (S)-Salsolinol 27740-96-1 99.64%
    (S)-Salsolinol ((-)-Salsolinol) is a dopamine-derived endogenous metabolite.
    (S)-Salsolinol
  • HY-113616A
    VU0364572 TFA 1240514-89-9 99.27%
    VU0364572 TFA is an orally active and selective allosteric agonist of the M1 muscarinic receptor with an EC50 of 0.11 μM. VU0364572 TFA has neuroprotective potential for preventing memory impairments and reducing neuropathology in Alzheimer’s Disease. VU0364572 TFA is CNS penetrant.
    VU0364572 TFA
  • HY-B0075S1
    Melatonin-d3 90735-69-6 99.15%
    Melatonin-d3 is the deuterium labeled Melatonin. Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress.
    Melatonin-d3
  • HY-N0473S2
    L-Tyrosine-13C6 201595-63-3 99.90%
    L-Tyrosine-13C6 is the 13C-labeled L-Tyrosine. L-Tyrosine is a non-essential amino acid which can inhibit citrate synthase activity in the posterior cortex.
    L-Tyrosine-13C6
  • HY-P991045
    Donanemab (Mouse IgG2a) 99%
    Donanemab (Mouse IgG2a) (mE8-IgG2a) is a mouse-derived IgG2 monoclonal antibody used in the research of Alzheimer's disease.
    Donanemab (Mouse IgG2a)
  • HY-W007970
    H-Phe-Phe-OH 2577-40-4
    H-Phe-Phe-OH is a peptide made of two phenylalanine molecules; Phenylalanine is an essential amino acid and the precursor for the amino acid tyrosine.
    H-Phe-Phe-OH
  • HY-W014941
    (R)-(-)-α-Methylhistamine dihydrochloride 75614-89-0 ≥99.0%
    (R)-(-)-α-Methylhistamine dihydrochloride is a potent, selective and brain-penetrant agonist of H3 histamine receptor, with a Kd of 50.3 nM. (R)-(-)-α-Methylhistamine dihydrochloride can enhance memory retention, attenuates memory impairment in rats.
    (R)-(-)-α-Methylhistamine dihydrochloride
  • HY-W016443
    L-m-Tyrosine 587-33-7 ≥98.0%
    L-m-Tyrosine is an unnatural amino acid. L-m-Tyrosine reduces dopamine, norepinephrine and serotonin in rats. L-m-Tyrosine has potential in the research of Parkinsons disease, Alzheimers disease, and arthritis.
    L-m-Tyrosine
  • HY-W762011
    BDE 47 5436-43-1 98.37%
    BDE 47 targets mitochondria, inhibits mitochondrial oxidative phosphorylation (OXPHOS), decreases mitochondrial membrane potential (MMP) and induces apoptosis in embryonic cell. BDE 47 induces the generation of ROS, and activates the JNK signaling pathway. BDE 47 exhibits embryonic developmental toxicity in zebrafish.
    BDE 47
  • HY-Y0966S4
    Glycine-1-13C 20110-59-2 ≥99.0%
    Glycine-1-13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-1-13C
Cat. No. Product Name / Synonyms Application Reactivity